Neurocrine biosciences announces regulatory approval of dysval® (valbenazine) for the treatment of tardive dyskinesia in japan

San diego , march 28, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that its collaboration partner, mitsubishi tanabe pharma corporation (mtpc), obtained regulatory approval of dysval® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the japanese ministry of health, labour and welfare on march 28, 2022. mtpc made a public announcement, which is available here: mtpc announcement neurocrine biosciences and mtpc collaboration details in march 2015, neurocrine biosciences entered into a collaboration and license agreement with mtpc for the development and commercialization of valbenazine capsules for movement disorders in japan and other select asian markets.
NBIX Ratings Summary
NBIX Quant Ranking